Carbenoxolone

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Carbenoxolone
Carbenoxolone.png
Systematic (IUPAC) name
(3β)-3-[(3-carboxypropanoyl)oxy]-11-oxoolean-12-en-30-oic acid
OR
(2S,4aS,6aS,6bR,8aR,10S,12aS,12bR,14bR)-10-(3-carboxypropanoyloxy)-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid
Clinical data
AHFS/Drugs.com International Drug Names
Legal status
?
Identifiers
CAS number 5697-56-3 N
ATC code A02BX01
PubChem CID 636403
DrugBank DB02329
ChemSpider 552190 YesY
UNII MM6384NG73 YesY
ChEMBL CHEMBL499915 YesY
Chemical data
Formula C34H50O7 
Mol. mass 570.765 g/mol
 N (what is this?)  (verify)

Carbenoxolone, a synthetic derivative of glycyrrhetinic acid, is a licensed drug (in the UK) for oesophageal ulceration and inflammation. Other uses include treatment of oral and perioral lesions.

Carbenoxolone (aka Carbenoxolone, CBX) is also used as a blocker of the enzyme 11β-hydroxysteroid dehydrogenase (11β-HSD), of pannexon membrane channels (comprising 6 subunits of pannexin) and the related innexon channels (consisting of invertebrate innexins), and at higher concentrations, as a blocker of connexon channels ("hemichannels" made up of 6 connexin subunits each) and of gap junctions (2 connexons joined together). Animal and in vitro studies suggest that this blockade can increase insulin sensitivity.[citation needed]

Nootropic effects[edit]

Carbenoxolone has also been investigated for nootropic effects.[1]

This research started from an observation that long-term exposure to glucocorticoids may have negative effects on cognition. Carbenoxolone may decrease the amount of active glucocortocoid in the brain, because the drug inhibits 11Beta-hydroxysteroid dehydrogenase type 1, an enzyme which regenerates cortisol, an active glucocorticoid, from inactive cortisone. In the research trial investigating this use of carbenoloxone, it was shown that the drug improved verbal fluency in elderly healthy men (aged 55–75). In type 2 diabetics aged 52–70, the drug improved verbal memory. However, potassium-sparing diuretic amiloride was co-administered with carbenoxolone, since carbenoxolone used by itself may cause hypertension by increasing cortisol in the kidneys.

References[edit]

  1. ^ Sandeep TC, Yau JL, MacLullich AM, et al. (2004). "11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics". Proc. Natl. Acad. Sci. U.S.A. 101 (17): 6734–9. doi:10.1073/pnas.0306996101. PMC 404114. PMID 15071189.